États-Unis - anglais - NLM (National Library of Medicine)

state of florida doh central pharmacy - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg - the use of metoclopramide  tablets is recommended for adults only. therapy should not exceed 12 weeks in duration. metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. metoclopramide tablets, usp are indicated for the relief

États-Unis - anglais - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 10 mg - the use of metoclopramide  tablets is recommended for adults only. therapy should not exceed 12 weeks in duration. metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. metoclopramide tablets, usp are indicated for the relief

États-Unis - anglais - NLM (National Library of Medicine)

rebel distributors corp - metoclopramide hydrochloride (unii: w1792a2rvd) (metoclopramide - unii:l4yeb44i46) - metoclopramide 5 mg - the use of metoclopramide  tablets is recommended for adults only. therapy should not exceed 12 weeks in duration. metoclopramide tablets are indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux who fail to respond to conventional therapy. the principal effect of metoclopramide is on symptoms of postprandial and daytime heartburn with less observed effect on nocturnal symptoms. if symptoms are confined to particular situations, such as following the evening meal, use of metoclopramide as single doses prior to the provocative situation should be considered, rather than using the drug throughout the day. healing of esophageal ulcers and erosions has been endoscopically demonstrated at the end of a 12-week trial using doses of 15 mg q.i.d. as there is no documented correlation between symptoms and healing of esophageal lesions, patients with documented lesions should be monitored endoscopically. metoclopramide tablets, usp are indicated for the relief of

États-Unis - anglais - NLM (National Library of Medicine)

ncs healthcare of ky, llc dba vangard labs - lorazepam (unii: o26fzp769l) (lorazepam - unii:o26fzp769l) - lorazepam 0.5 mg - lorazepam is indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety or anxiety associated with depressive symptoms. anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. the effectiveness of lorazepam in long-term use, that is, more than 4 months, has not been assessed by systematic clinical studies. the physician should periodically reassess the usefulness of the drug for the individual patient. lorazepam is contraindicated in patients with     -     hypersensitivity to benzodiazepines or to any components of the formulation.     -     acute narrow-angle glaucoma.

États-Unis - anglais - NLM (National Library of Medicine)

novel laboratories, inc. - temazepam (unii: chb1qd2qss) (temazepam - unii:chb1qd2qss) - temazepam 7.5 mg - temazepam capsules, usp are indicated for the short-term treatment of insomnia (generally 7 to 10 days). for patients with short-term insomnia, instructions in the prescription should indicate that temazepam capsules, usp should be used for short periods of time (7 to 10 days). the clinical trials performed in support of efficacy were 2 weeks in duration with the final formal assessment of sleep latency performed at the end of treatment. benzodiazepines may cause fetal harm when administered to a pregnant woman. an increased risk of congenital malformations associated with the use of diazepam and chlordiazepoxide during the first trimester of pregnancy has been suggested in several studies. transplacental distribution has resulted in neonatal cns depression following the ingestion of therapeutic doses of a benzodiazepine hypnotic during the last weeks of pregnancy. reproduction studies in animals with temazepam were performed in rats and rabbits. in a perinatal-postnatal study in rats, oral doses of 60 mg/

États-Unis - anglais - NLM (National Library of Medicine)

eon labs, inc. - carisoprodol (unii: 21925k482h) (carisoprodol - unii:21925k482h), aspirin (unii: r16co5y76e) (aspirin - unii:r16co5y76e), codeine phosphate (unii: gsl05y1mn6) (codeine anhydrous - unii:ux6owy2v7j) - carisoprodol 200 mg - carisoprodol, aspirin and codeine phosphate tablets, usp are indicated for the relief of discomfort associated with acute, painful musculoskeletal conditions in adults. limitations of use carisoprodol, aspirin and codeine phosphate tablets, usp should only be used for short periods (up to two or three weeks) because adequate evidence of effectiveness for more prolonged use has not been established and because acute, painful musculoskeletal conditions are generally of short duration (see dosage and administration ). carisoprodol, aspirin and codeine phosphate tablets are contraindicated for: • all children younger than 12 years of age (see warnings) • post-operative management in children younger than 18 years of age following tonsillectomy and/or adenoidectomy (see warnings ). carisoprodol, aspirin and codeine phosphate tablets are also contraindicated in patients with: carisoprodol, aspirin, and codeine phosphate tablets contains codeine. codeine in combination with carisoprodol and aspirin is a schedule iii

États-Unis - anglais - NLM (National Library of Medicine)

actavis pharma, inc. - oxycodone hydrochloride (unii: c1enj2te6c) (oxycodone - unii:cd35pmg570), acetaminophen (unii: 362o9itl9d) (acetaminophen - unii:362o9itl9d) - oxycodone hydrochloride 2.5 mg - oxycodone and acetaminophen tablets, usp are indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. limitations of use because of the risks of addiction, abuse, and misuse, with opioids, even at recommended doses [see warnings ], reserve oxycodone and acetaminophen tablets for use in patients for whom alternative treatment options [e.g., non-opioid analgesics] - have not been tolerated, or are not expected to be tolerated, - have not provided adequate analgesia, or are not expected to provide adequate analgesia oxycodone and acetaminophen tablets are contraindicated in patients with:  - significant respiratory depression [see warnings ] - acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment [see warnings ] - known or suspected gastrointestinal obstruction, including paralytic ileus [see warnings ] - hypersensitivity to oxycodone, acetaminophen, or any other component of the produc

États-Unis - anglais - NLM (National Library of Medicine)

prasco laboratories - mefenamic acid (unii: 367589pj2c) (mefenamic acid - unii:367589pj2c) - mefenamic acid 250 mg - carefully consider the potential benefits and risks of mefenamic acid and other treatment options before deciding to use mefenamic acid. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings ;   g astrointestinal  bleeding, ulceration, and perforation ). mefenamic acid is indicated: - for relief of mild to moderate pain in patients ≥ 14 years of age, when therapy will not exceed one week (7 days). - for treatment of primary dysmenorrhea. mefenamic acid is contraindicated in the following patients. - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to mefenamic acid or any components of the drug product (see warnings ;  anaphylactic reactions , serious skin reactions ). - history of asthma, urticarial, or other allergic-type reactions after taking aspirin or other nsaids.  severe, sometimes fatal, anaphylactic reactions to nsaids have been reported in such patients (see warnings;    anaphylactic reaction,

États-Unis - anglais - NLM (National Library of Medicine)

mckesson corporation - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 15 mg - morphine sulfate extended-release tablets  are indicated for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. limitations of use morphine sulfate extended-release tablets are contraindicated in patients with: clinical considerations fetal/neonatal adverse reactions prolonged use of opioid analgesics during pregnancy for medical or nonmedical purposes can result in physical dependence in the neonate and neonatal opioid withdrawal syndrome shortly after birth. observe newborns for symptoms of neonatal opioid withdrawal syndrome, such as poor feeding, diarrhea, irritability, tremor, rigidity, and seizures, and manage accordingly [see warnings and precautions (5.3)]. teratogenic effects (pregnancy category c) there are no adequate and well-controlled studies in pregnant women. morphine sulfate extended-release tablets should be used during pregnancy only if the potential benefit justifies the potential r

États-Unis - anglais - NLM (National Library of Medicine)

west-ward pharmaceutical corp - primidone (unii: 13afd7670q) (primidone - unii:13afd7670q) - primidone 250 mg - primidone tablets, usp used alone or concomitantly with other anticonvulsants, are indicated in the control of grand mal, psychomotor, and focal epileptic seizures. it may control grand mal seizures refractory to other anticonvulsant therapy. primidone is contraindicated in: - patients with porphyria and - patients who are hypersensitive to phenobarbital (see clinical pharmacology ).